FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 340:1374 April 29, 1999 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

Edited by Raymond F. Schinazi, Jean-Pierre Sommadossi, and Howard C. Thomas. 451 pp. London, International Medical Press, 1998. $129. ISBN 1-901769-01-1.

Therapies for viral hepatitis, mainly hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis delta virus (HDV), and hepatitis G virus infection, are a matter of concern for many physicians, not only specialists in gastroenterology and hepatology but also for internists, virologists, and others. An estimated 2 billion people have or have had HBV infection, and another 350 million people are HBV carriers, representing a huge reservoir of virus and spreading the disease to nonvaccinated populations. In addition, HDV infection can be associated with HBV infection. HCV, discovered more than 10 years ago, is also widespread, mainly among patients who . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.